Sleep depth and fatigue: role of cellular inflammatory activation.

TitleSleep depth and fatigue: role of cellular inflammatory activation.
Publication TypeJournal Article
Year of Publication2011
AuthorsThomas KMS, Motivala S, Olmstead R, Irwin MR
JournalBrain Behav Immun
Volume25
Issue1
Pagination53-8
Date Published2011 Jan
ISSN1090-2139
KeywordsAdult, Cytokines, Fatigue, Female, Humans, Inflammation, Interleukin-6, Male, Middle Aged, Monocytes, Polysomnography, Sleep, Sleep Stages, Sleep, REM, Surveys and Questionnaires, Tumor Necrosis Factor-alpha, Young Adult
Abstract

Individuals with underlying inflammation present with a high prevalence of non-specific co-morbid symptoms including sleep disturbance and fatigue. However, the association between cellular expression of proinflammatory cytokines, alterations of sleep depth and daytime fatigue has not been concurrently examined. In healthy adults (24-61 years old), evening levels of monocyte intracellular proinflammatory cytokine production were assessed prior to evaluation of polysomnographic sleep and measures of fatigue the following day. Stimulated monocyte production of interleukin-6 (IL-6), but not tumor necrosis factor α (TNF-α), was negatively associated with slow wave sleep (ΔR²=.17, p=.029). In contrast, stimulated monocyte production of IL-6 was positively associated with rapid-eye movement (REM) sleep duration during the first sleep cycle (ΔR²=.26, p<.01). Moreover, evening stimulated production of IL-6 was associated with fatigue the following day (ΔR²=.17, p=.05). Mediation analyses showed that slow wave sleep, but not REM sleep duration, mediated the relationship between evening levels of IL-6 production and daytime fatigue. These results indicate that increases in stimulated monocyte production of IL-6 may be associated with decreases in slow wave sleep and increases in REM sleep duration. Relative loss of slow wave sleep may be one pathway through which cellular inflammation leads to daytime fatigue.

DOI10.1016/j.bbi.2010.07.245
Alternate JournalBrain Behav. Immun.
PubMed ID20656013
PubMed Central IDPMC2991567
Grant ListAG 026364 / AG / NIA NIH HHS / United States
CA 10014152 / CA / NCI NIH HHS / United States
CA116778 / CA / NCI NIH HHS / United States
HL 079955 / HL / NHLBI NIH HHS / United States
L60 MD003159-01 / MD / NIMHD NIH HHS / United States
P30 AG028748 / AG / NIA NIH HHS / United States
P30-AG028748 / AG / NIA NIH HHS / United States
R01 AG026364 / AG / NIA NIH HHS / United States
R01 AG034588 / AG / NIA NIH HHS / United States
RR00827 / RR / NCRR NIH HHS / United States
T32 MH019925 / MH / NIMH NIH HHS / United States
T32 MH019925-09 / MH / NIMH NIH HHS / United States
T32-MH19925 / MH / NIMH NIH HHS / United States